MSDC-0160, a new insulin sensitizer called a mTOT Modulator, is being developed to treat patients diagnosed with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
MSDC-0160 successfully completed a Phase 2a clinical trial at Rush University Medical Center (Chicago) in patients diagnosed with mild dementia due to Alzheimer’s disease. The study was funded by the Alzheimer’s Drug Discovery Foundation. MSDC-0160 is also being studied in preclinical models of Parkinson’s disease, in collaboration with researchers at Van Andel Institute (Grand Rapids, Michigan), A 90-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose Phase 2b clinical study in 258 patients with type 2 diabetes was completed in December 2011. Data from this study was published in Clinical Pharmacology & Therapeutics (advance online publication 6 March 2013).
MSDC has discovered a series of novel insulin sensitizers for the treatment of type 2 diabetes that do not bind or agonize PPARγ. These compounds constitute new structure classes that are not TZDs; yet, non-clinical in vivo data in mouse models of diabetes have shown similar insulin sensitizing pharmacology. Additional preclinical evaluation is ongoing.